MedTrace Logo

Screening Platform for Clinical Trials in Advanced Colorectal Cancer

NCT01723969 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 668

Last updated 2022-07-07

No results posted yet for this study

Summary

The EORTC GastroIntestinal Tract Cancer Group and the EORTC HeadQuarters wish to set up a European screening platform for advanced colo-rectal cancer (CRC) patients. The goal of this screening platform is to provide quick access to new drugs to patients by offering a new structure for clinical trials.

Currently some of the most challenging clinical questions arise from the molecular sub-division of CRC that would theoretically allow to inhibit the specific, altered pathways in the patients.

A major problem for trials in this "personalized medicine" is that the low frequency of the different mutations requires a high effort for screening and identifying the patients.

The EORTC CRC screening platform will hopefully offer a feasible and efficient way to characterize the patients on the molecular basis of their tumors and allow to offer them rapid and preferential participation in clinical studies with new drugs targeted to their specific pathway alterations.

Conditions

Interventions

GENETIC

Tumour markers testing

Tumour markers testing in patients advanced or metastatic colo-rectal cancer.

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Gunnar Folprecht, MD · Universitaetsklinikum Carl Gustav Carus, Dresden, DE

  • Sabine Tejpar, MD, PhD · U.Z. Leuven - Campus Gasthuisberg, Leuven, BE

  • Daniela Aust, MD · Universitaetsklinikum Carl Gustav Carus, Dresden, DE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2019-04-10
Completion
2020-03-10

Countries

  • Belgium
  • Cyprus
  • France
  • Germany
  • Greece
  • Italy
  • Poland
  • Portugal
  • Spain
  • Sweden
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01723969 on ClinicalTrials.gov